JS207
JS207 is a humanized IgG4-specific antibody targeting PD-1 and VEGFA. JS207 can block PD-1/PD-L1, PD-1/PD-L2, and VEGFA/VEGFR2 interactions, with IC50 values of 6.37 nM, 4.3 nM, and 3.35 nM, respectively. JS207 can relieve immunosuppression, promote T cell activation and IL-2/IFN-γ release, and induce PD-1 internalization. JS207 can inhibit VEGF-driven angiogenesis and has the property that VEGFA enhances PD-1 internalization. JS207 cross-reacts with cynomolgus monkey PD-1/VEGFA and rat/mouse VEGFA, but does not bind rat/mouse PD-1. JS207 shows antitumor efficacy in mouse colon cancer and melanoma models. JS207 can be used for research related to colon cancer and melanoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All VEGFR Isoforms
More
Biological Activity
Description
Species Reactivity
Human
In Vitro
JS207 binds human PD-1 with an EC50 of 10.4 ng/mL (58.6 pM) and is specific for related immune proteins[1].
JS207 cross-reacts with human and cynomolgus monkey PD-1 as well as human, cynomolgus monkey, rat, and mouse VEGFA[1].
JS207 (2 μg/mL) binds human PD-1 with a KD of 0.46 nM[1].
JS207 (30 nM; 0.5-4 h) induced PD-1 internalization in H293/PD-1 cells, reaching up to 65% in the presence of VEGFA[1].
JS207 (15 pM-150 nM; 5 days) promotes IL-2 and IFN-γ release in the MLR assay[1].
JS207 specifically binds to human VEGFA but does not bind to other human VEGF family proteins[1].
JS207 binds human VEGFA with a KD of 9 pM[1].
JS207 inhibits VEGFA/VEGFR2 signaling in the H293/VEGFR2 reporter gene assay with an IC50 of 0.773 nM[1].
JS207 (0.005-10 nM; 96 h) inhibits VEGFA-induced HUVEC proliferation with an IC50 of 0.296 nM[1].
JS207 can simultaneously bind to human PD-1 and human VEGFA[1].
JS207 blocks PD-1/PD-L1 in Jurkat/PD-1 and CHO/PD-L1 reporter gene assays with an EC50 of 2.89 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JS207 (1.0-10.0 mg/kg; intraperitoneal injection; twice weekly; 6 doses total) produces dose-dependent tumor growth inhibition in the A375 melanoma NDG mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6-Pdcd1tm1(PDCD1)Bcgen/Bcgen (B-hPD-1 humanized mice)[1]
-
Dosage:0.75 mg/kg, 1.5 mg/kg, and 4.5 mg/kg
-
Administration:intraperitoneally; twice weekly; for 6 doses
-
Result:Significantly inhibited tumor growth dose-dependently at 0.75, 1.5, and 4.5 mg/kg, achieving tumor growth inhibition (TGI) rates of 76.1%, 78.0%, and 84.4%, respectively, at day 20.
-
Animal Model:NDG mice were implanted subcutaneously with A375 cells at 5×106 cells/mouse suspended and mixed with Matrigel[1]
-
Dosage:1.0 mg/kg, 3.0 mg/kg, and 10.0 mg/kg
-
Administration:intraperitoneally; twice weekly; for 6 doses
-
Result:In the saline group, the mean tumor volume reached 585 mm3 at day 21.
At 1, 3, and 10 mg/kg, mean tumor volumes were 362 mm3, 344 mm3, and 262 mm3, corresponding to TGI rates of 49.6%, 53.7%, and 72.0%, respectively.
Target
PD-1 & VEGF
Conjugated
Unconjugated
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[JS207]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JS207 Related Classifications
HY-P992548 Related Classifications
Powered by Bioz